Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

This case report describes a 3-year-old boy with trichothiodystrophy, highlighting specific MRI findings of diffuse dysmyelination and osteosclerosis that may be unique to the disorder.

In this case report, a 14-year-old male with alopecia areata subtotalis and nail involvement showed significant improvement after 9 months of treatment with oral tofacitinib, including complete hair regrowth and nail texture improvement, though further studies are needed to confirm these findings.

This report describes the diagnosis and treatment of traumatic anserine folliculosis in children, highlighting its distinct skin features and suggesting tretinoin cream as an effective remedy.

This article reviews clinical issues and dermatologist perspectives on managing periungual lesions in patients undergoing docetaxel chemotherapy, but it reports no new clinical outcomes.

This study found that dimethylarsinic acid significantly accelerates skin tumor development in hair follicle-targeted K6/ODC transgenic mice.

This study found that intramuscular triamcinolone acetonide may be an effective and safe treatment option for managing refractory alopecia areata, showing a 63% response rate in patients and hair regrowth negatively correlated with initial scalp involvement.

In this study, a taurine-based ionic liquid was developed to effectively penetrate the skin barrier and deliver antioxidants to hair follicles, reducing oxidative stress and promoting hair regrowth in an androgenic alopecia animal model.

In this article, the authors detail their experience with AltrenoTM, a new topical retinoid lotion used for treating mild to moderate acne, reporting clinical effectiveness and satisfactory tolerability among patients of various ages, including children as young as 9.

This study suggests that bioactive ceramics could be an effective universal strategy for treating musculoskeletal disorders by targeting the Piezo1-modulated intracellular calcium pathway during bone and muscle formation.

This study investigated alopecia areata in a mouse model, finding that tofacitinib may inhibit disease progression by modulating linoleic acid metabolism and magnesium pathways, particularly affecting CD8+ T cell infiltration in hair follicles, offering insights for potential treatments.

In this study, combining topical calcipotriol with mometasone results in greater improvement in alopecia areata treatment compared to using mometasone alone, as evidenced by a more significant reduction in SALT score over 24 weeks.

This abstract describes the initial success of intralesional cidofovir for SCC treatment and states that it has not shown systemic toxicity, but it does not report new clinical trial results.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

This review provides a synopsis of 53 cases of temporal triangular alopecia, noting its frequent detection in early childhood and potential association with congenital diseases, but it reports no new clinical findings.

This study suggests that applying topical Tempol to the scalp before whole brain radiation may protect against radiation-induced alopecia and is safe and well-tolerated.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

This study found that skin exposure to toluene diisocyanate in mice creates immune-recognition reservoirs in the skin's stratum corneum and hair follicles, potentially leading to sensitization and allergic reactions.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

This study in mice found that using modified illite as a carrier for topical minoxidil enabled effective delivery without the solvent toxicity typically associated with minoxidil, while the illite also promoted hair growth through anti-inflammatory and pro-proliferative mechanisms.

This open-access journal publishes innovative research articles across various fields but reports no new clinical results in this summary.

Triamcinolone acetonide injections help regrow hair in alopecia areata patients.

This study reported that while Intralesional Triamcinolone Acetonide injections effectively improved mouth opening in patients with Oral Submucous Fibrosis, it also led to symptoms of Cushing's Syndrome, highlighting the need for careful monitoring of adverse effects.

This study found that a topical gel containing Minoxidil and Tofacitinib citrate showed promise for treating alopecia areata, with formulation F5 demonstrating effective drug release and stability in evaluations.

This case report details a 23-year-old woman who was poisoned with thallium by a colleague and treated with activated charcoal and Prussian blue.

This study reported that nanoemulsions significantly improved the skin permeability of thiocolchicoside compared to its aqueous solution, suggesting they are effective carriers for its transdermal delivery.

This study found that ossification in trichilemmal cysts may be more common than previously thought, often associated with cyst wall rupture, and reports a novel case of ossifying TC with extramedullary hematopoiesis.

In this study, lecithin/n-propanol/isopropyl myristate/water/tetracaine hydrochloride microemulsion was found to be a safe carrier for transdermal drug delivery in animal models, with analgesic effects on Wistar rats.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

This study found that Tideglusib at 50nM stimulated Type-I collagen production in human gingival fibroblasts and osteoblasts, suggesting potential benefits for bone regeneration.